Latigo Biotherapeutics (LTGO) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$27.59
- Estimate
- -$0.66
- Surprise
- -4048.9%
- Score today
- 5.1/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Latigo Biotherapeutics (LTGO) reported a wider loss than forecast — adjusted EPS of -$27.59 against the -$0.66 estimate (a 4048.9% shortfall).
Coverage in the report window
- Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY — benzinga, 2026-09-03
- Leerink Partners Initiates Coverage On Latigo Biotherapeutics with Outperform Rating, Announces Price Target of $36 — benzinga, 2026-09-01
- Jefferies Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50 — benzinga, 2026-09-01
Where TrendMatrix's rating stands now
TrendMatrix currently rates LTGO Sell at 5.1/10; no pre/post engine snapshot brackets this report.
1 of the last 2 quarters beat the estimate; this quarter's -4048.9% surprise compares with a -2021.0% four-quarter average. Next scheduled report: 2027-03-18.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $52.25 vs price $13.11 — ratio 4.0×). Rejected, falling back to technical TP.
- Quality below floor (2.9 < 4.0)
- Momentum score 4.1/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $13.11
- Price target
- $17.32
- Stop
- $12.19
- Upside to target
- +32.1%
Risk check: trading volume is running 1.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.
LTGO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $869.2M
- P/E (fwd)
- -6.3
- 52-week range
- $10.24–$25.93
- Off 52-week high
- 49.4%
- RSI (14)
- 36
- Volume vs avg
- 1.54×
- Score today
- 5.1/10